Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
  • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Prostones have also been known to be useful in the ophthalmic field, for example, for lowering intraocular pressure and treating glaucoma (USPs 5,001,153, 5,151,444, 5,166,178, 5,194,429 and 5,236,907), for treating cataract (USPs 5,212,324 and 5 , 686 , 487 ) , for increasing the choroidal blood flow (USP 5,221,690), for treating optic nerve disorder (USP 5,773,471), the contents of these references are herein incorporated by reference.
• Ophthalmic solution comprising (+) -isopropyl (Z) -7- [ (1R, 2R, 3R, 5S) -3 , 5-dihydroxy-2- (3-oxodecyl)
• preferred substituents on the carbon atom at position (s) 3, 17, 18 and/or 19 include alkyl having 1-4 carbon atoms, especially methyl and ethyl.
• Preferred substituents on the carbon atom at position 16 include lower alkyls such as methyl and ethyl, hydroxy, halogen atom such as chlorine and fluorine, and aryloxy such as trifluoromethylphenoxy .
• Preferred substituents on the carbon atom at position 17 include lower alkyl such as methyl and ethyl, hydroxy, halogen atom such as chlorine and fluorine, and aryloxy such as trifluoromethylphenoxy.
• Preferred substituents on the carbon atom at position 20 include saturated or unsaturated lower alkyl such as Ci - 4 alkyl, lower alkoxy such as C 1 - 4 alkoxy, and lower alkoxy alkyl such as Ci -4 alkoxy- Ci- 4 alkyl.
• Preferred substituents on the carbon atom at position 5 include halogen atoms such as chlorine and fluorine.
• Preferred substituents on the carbon atom at position 6 include an oxo group forming a carbonyl group.
• Stereochemistry of PGs having hydroxy, lower alkyl or hydroxy (lower) alky1 substituent on the carbon atom at positions 9 and 11 may be a, ⁇ or a mixture thereof.
• the term "unsaturated" in the definitions for Ri and Ra is intended to include at least one or more double bonds and/or triple bonds that are isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to the usual nomenclature, an unsaturated bond between two serial positions is represented by denoting the lower number of the two positions, and an unsaturated bond between two distal positions is represented by denoting both of the positions.
• cyclo (lower) alkyl refers to a cyclic group formed by cyclization of a lower alkyl group as defined above but contains three or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• aryloxy refers to a group represented by the formula ArO- , wherein Ar is aryl as defined above.
• Suitable "pharmaceutically acceptable salts” include salts formed with non-toxic bases conventionally used in pharmaceutical field, for example a salt with an inorganic base such as an alkali metal salt (such as sodium salt and potassium salt) , an alkaline earth metal salt (such as calcium salt and magnesium salt) , an ammonium salt; or a salt with an organic base, for example, an amine salt (such as methylamine salt, dimethylamine salt,
• cyclohexylamine salt benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris (hydroxymethylamino) ethane salt, monomethyl- monoethanolamine salt, procaine salt and caffeine salt) , a basic amino acid salt (such as arginine salt and lysine salt), tetraalkyl ammonium salt and the like.
• a basic amino acid salt such as arginine salt and lysine salt
• tetraalkyl ammonium salt and the like.
• ethers examples include alkyl ethers, for example, lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, t-butyl ether, pentyl ether and 1-cyclopropyl ethyl ether; and medium or higher alkyl ethers such as octyl ether, diethylhexyl ether, lauryl ether and cetyl ether; unsaturated ethers such as oleyl ether and linolenyl ether; lower alkenyl ethers such as vinyl ether, allyl ether;
• lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, t-butyl ether, pentyl ether and 1-
• lower alkynyl ethers such as ethynyl ether and propynyl ether; hydroxy (lower) alkyl ethers such as hydroxyethyl ether and hydroxyisopropyl ether; lower alkoxy (lower) alkyl ethers such as methoxymethyl ether and 1-methoxyethyl ether; optionally substituted aryl ethers such as phenyl ether, tosyl ether, t-butylphenyl ether, salicyl ether, 3 , 4-di-methoxyphenyl ether and benzamidophenyl ether; and aryl (lower) alkyl ethers such as benzyl ether, trityl ether and benzhydryl ether.
• aryl (lower) alkyl ester such as benzyl ester, trityl ester and benzhydryl ester.
• Ra is a hydrocarbon containing 1-10 carbon atoms, more preferably, 1-8 carbon atoms. Ra may have one or two side chains each having one carbon atom.
• the configuration of the ring and the a- and/or ⁇ chains in the above formula (I) and (II) may be the same as or different from that of the prostanoic acid.
• the present invention also includes a mixture of a compound having a primary type configuration and a compound of a non-primary type configuration.
• the fatty acid derivative used in the invention include the bicyclic compound and analogs or derivatives thereof.
• any of isomers such as the individual tautomeric isomers, the mixture thereof, or optical isomers, the mixture thereof, a racemic mixture, and other steric isomers may be used in the same purpose.
• the fatty acid derivative described as above is useful for treating macular edema.
• the compound can effectively treat macular edema by administering the same to the patient via non invasive route, for example, ocular topical administration such as instillation of eye drops.
• treatment refers to any means of control of a condition including prevention, cure, relief of the condition, attenuation of the condition and arrest of progression.
• the fatty acid derivative may preferably be formulated as a pharmaceutical composition suitable for the desired administration by a conventional procedure to provide said composition.
• the pharmaceutical composition may be those suitable for ocular topical administration, oral administration, intranasal administration, inhalation, intravenous administration including intravenous drip injection, subcutaneous administration and infusion, rectal administration, vaginal administration, or transdermal administration.
• the amount of the above-defined the fatty acid derivative in the pharmaceutical composition of the present invention may vary depending on the formulation of the composition and can generally be within a range of 0.001- 10.0 w/v%, more preferably 0.001-5.0 w/v%, and most
• a soft capsule may be further dissolved in a proper solvent such as fatty acid or a mo-, di- or triglyceride thereof to obtain a soft capsule.
• a proper solvent such as fatty acid or a mo-, di- or triglyceride thereof.
• the ophthalmic solution was instilled two drops per one time administration (with 5 minute interval) , twice a day for 24 weeks. Before (0 week) and after (24 weeks) the treatment, macular of the patient's eye were evaluated. The evaluation was performed by confirming the presence or absence of edema or cyst using an optical interference tomograph (OCT) . The results are shown in Table 1.
• Animals GD79B rabbit (pigmented). Each group contains 8 animals .

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Ophthalmology & Optometry (AREA)
• Epidemiology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Priority Applications (5)

Applications Claiming Priority (10)

Publications (1)

Family

ID=44798822

Family Applications (2)

Family Applications After (1)

Country Status (9)

Cited By (3)

Families Citing this family (7)

Family Cites Families (7)

• 2011
  • 2011-04-12 CA CA2795720A patent/CA2795720A1/en not_active Abandoned
  • 2011-04-12 KR KR1020127029449A patent/KR20130050939A/ko not_active Withdrawn
  • 2011-04-12 JP JP2012547193A patent/JP5686819B2/ja not_active Expired - Fee Related
  • 2011-04-12 AR ARP110101238A patent/AR080888A1/es unknown
  • 2011-04-12 US US13/084,927 patent/US20110275715A1/en not_active Abandoned
  • 2011-04-12 EP EP11768978.6A patent/EP2558104A4/en not_active Withdrawn
  • 2011-04-12 EP EP11768976.0A patent/EP2558103A4/en not_active Withdrawn
  • 2011-04-12 CN CN201180028968XA patent/CN102933217A/zh active Pending
  • 2011-04-12 TW TW100112738A patent/TW201204366A/zh unknown
  • 2011-04-12 WO PCT/JP2011/059474 patent/WO2011129457A1/en not_active Ceased
  • 2011-04-12 TW TW100112624A patent/TW201141486A/zh unknown
  • 2011-04-12 JP JP2012544363A patent/JP5878128B2/ja active Active
  • 2011-04-12 KR KR1020127029562A patent/KR20130099812A/ko not_active Withdrawn
  • 2011-04-12 US US13/084,982 patent/US20110275711A1/en not_active Abandoned
  • 2011-04-12 CA CA2795723A patent/CA2795723A1/en not_active Abandoned
  • 2011-04-12 WO PCT/JP2011/059479 patent/WO2011129461A1/en not_active Ceased
  • 2011-04-12 CN CN2011800290140A patent/CN102946883A/zh active Pending
• 2015
  • 2015-09-30 JP JP2015194346A patent/JP2016026182A/ja active Pending

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events